Bio-Rad Laboratories Reports Q1 2026 Earnings Amid Regional Challenges

Bio-Rad Laboratories reported mixed performance in its first quarter of 2026 due to the Middle East conflict and delayed NIH funding impacts. The company lowered full-year revenue guidance, citing ongoing regional headwinds and operational adjustments.

By Moby Intelligence May 1, 2026 3 min read · Yahoo Finance · May 1, 2026, 12:30 UTC

Bio-Rad Laboratories Reports Q1 2026 Earnings Amid Regional Challenges

Tickers: $BIO

Topics: diagnostics digital_pcr life_science manufacturing_strategy revenue_guidance

Read the full article at Yahoo Finance

More World news

Donald Trump Suggests Tim Cook as Potential Successor for Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 16:09 UTC
Yankees President Randy Levine Advocates for Protect College Sports Act and Addresses MLB Labor Uncertainty CNBC · November 12, 2026, 15:34 UTC
Donald Trump Suggests Apple Chairman Tim Cook as Potential Successor to Nvidia CEO Jensen Huang TechCrunch · November 12, 2026, 16:12 UTC
Bybit Announces Title Partnership for Inaugural Stockholm Open ATP 250 Tournament PR Newswire · November 12, 2026, 16:11 UTC
SES AI Reports Q3 2026 Revenue Growth Amid Strategic Shift Toward Drone Battery Market Motley Fool · November 12, 2026, 16:10 UTC
Nvidia Shares Decline Following Resignation of CEO Jensen Huang Seeking Alpha · November 12, 2026, 16:07 UTC
Broadcom and Micron Identified as Top Alternatives to Nvidia Amid Leadership Uncertainty Motley Fool · November 12, 2026, 16:03 UTC
Thomson Reuters Executives to Present at TD Securities Technology Conference PR Newswire · November 12, 2026, 16:00 UTC
BHP to Restructure Australian Iron Ore Operations Amid Rising Costs Seeking Alpha · November 12, 2026, 15:59 UTC
Capri Investment Group and GRIT Chicago Unveil $10 Billion Bronzeville Lakefront Development Plan PR Newswire · November 12, 2026, 16:00 UTC